AstraZeneca Year-To-Date and Q3 2017 Results
A webcast for investors and analysts will take place on Thursday 9 November 2017 at 12:00 GMT.
Go to Webcast registration page
Annual reports
Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
-
US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
-
US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung cancer
-
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
-
Transparency Directive Voting Rights and Capital
-
Director/PDMR Shareholding
Upcoming events
Year-to-date and Q3 2017 Results
The Societe Generale Premium Review (management participation)
Berenberg European Healthcare Conference (management participation)
Sustainability
At AstraZeneca, we want to be valued and trusted by our stakeholders as a source of great medicines over the long term.
Our new sustainability strategy, ‘Securing our Future’, drives our enhanced efforts, sets a clear path for the years ahead and identifies ambitious commitments and targets. Our sustainability commitments are driven by our Purpose and Values and underpin our business model to support the delivery of our business strategy.
As we look ahead to pursuing our science-led strategy in the years up to 2025, we have identified three priority areas. We want to ensure that we broaden access to healthcare, minimise our environmental footprint, and ensure ethics and transparency underpin everything we do.
Read moreAnnual Report
2016
2015
2006-2014
Investor enquiries
Main Contacts
-
Annual Reports
Our Annual Report provides a wide range of information about our global business.
-
Shareholder FAQs
Answers to frequently asked shareholder questions.
-
Our Pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development
